STOCK MARKET BSE NSE

Rajnath Singh, Harsh Vardhan release first batch of DRDO's anti-COVID drug 2-DG

The drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’s Laboratories

Published: 17th May 2021 12:26 PM  |   Last Updated: 17th May 2021 01:29 PM   |  A+A-

Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan release first batch of Anti-COVID drug 2DG developed by DRDO

Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan release first batch of Anti-COVID drug 2DG developed by DRDO (Photo | ANI)

Express News Service

NEW DELHI: Defence Minister Rajnath Singh and Health Minister Harsh Vardhan on Monday released the first batch of the DRDO-developed anti-COVID drug 2DG here in the national capital. Singh expressed hope that the medicine would be beneficial in the fight against the pandemic.

“I thank all those who are associated in the research and development of this drug, including DRDO. 2-deoxy-D-glucose (2-DG) drug would be helpful in containing the virus. This is an example of our country’s scientific prowess,” Singh said after releasing the drug.

From Monday onwards, hospitals will receive the supplies. A total of 10,000 sachets of the drug will be supplied to several hospitals in Delhi.

The drug comes in a powder form in a sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.

Not only has the drug been found assisting in oxygen dependency, it also reduces the hospital stay of COVID-19 patients, said the Defence Minister.

“I have been informed that people who have been treated with this drug got well two-and-a-half days earlier. We have got to see that dependency on oxygen is reduced by 40 per cent. The best thing is it is in powder form which people can easily mix with water and use,” Rajnath said.

The drug 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’s Laboratories (DRL) in Hyderabad. It was given approval by the Drugs Controller General of India (DCGI) on May 8 for emergency use in moderate to severe cases of COVID-19. It was put through three phases of trials.

While assuring that the government is doing its best in dealing with the crisis across the country, the Defence Minister said there would be no impact on the borders.
 
“Our soldiers are full of energy and enthusiasm, guarding the borders. We all know how much bigger the challenges are, we will overcome them,” he said.

DRDO Chairman G Sateesh Reddy and AIIMS Director Randeep Guleria were also present on the occasion.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp